First photoactive drug to fight Parkinson's disease

June 8, 2018, University of Barcelona
First photoactive drug to fight Parkinson’s disease
Credit: Universidad de Barcelona

An international team has designed the first potentially therapeutic photoactive drug, MRS7145, to fight Parkinson's disease, according to the new article in Journal of Controlled Release.

This compound, which proved effective in laboratory animals in vivo, has been carried out by a team led by Francisco Ciruela, from the Faculty of Medicine and Health Sciences of the University of Barcelona, and collaborators.

Optopharmacology: beyond the limits of conventional drugs

Parkinson's is the second most common neurodegenerative disease after Alzheimer's and it affects more than 1 percent of the population. This disease, which affects the central nervous system, affects more than six million people worldwide, figures that could go higher than twelve million by 2030, according to data from the World Health Organization (WHO). In this disease, the neurotransmitter that controls the motor activity, dopamine, is reduced due the progressive death of dopaminergic neurons.

The action of is sometimes limited due several factors –lack of spatial specificity, slow and inaccurate distribution, etc.- which can reduce its therapeutic efficiency. Also, the efficiency of the traditional treatment on Parkinson's (levodopa) diminishes over time and it requires to increase the administration of the dose or to change the drug. The of new drugs (uncontrolled movements in the body, motor fluctuations, etc.) are another common denominator in most patients.

Optopharmacology is an innovative discipline based on the use of light –with a certain wave length- to control the activity of drugs. Therefore, light-sensitive drugs can act with a higher spatial and time precision and without creating adverse effects in the body.

MRS7145: opening the way to treat neurodegenerative diseases

The MRS7145, the first potentially therapeutic photoactive drug to fight Parkinson's, is a photo-sensitive derivate from SCH442416, a selective antagonist of adenosine A2A receptor. In scientific bibliography, some A2A antagonist receptors came up as potential drugs to fight Parkinson's, since they take part in the involved mechanisms in controlling the movement.

This photoactive drug is an inactive chemical compound that gets activated with light from a visible spectrum (with a 405 nm wave length) which is not harmful for the body. A series of optical fibers –planted in the striated bodies of laboratory animals- provide the irradiation of this area in the brain, which is responsible for the control of motor activity.

Lecturer Francisco Ciruela says, "once the striated body is radiated with violet light the active drug is released and blocks the adenosine A2A receptor. The blocking of adenosine receptors has an administrating effect on the activity of dopamine (pro-dopaminergic action)."

Photo-sensitive molecules that improve patients' quality of life

Improving the spatial and temporary precision of the drug and strengthening the commitment of the patient to the therapy are some of the benefits of optopharmacology in Parkinson's. "A fine time-space precision will enable manipulating the neural circuits in detail and set the functioning of those with therapeutic and neuroprotective purposes," says Ciruela.

"Nowadays, in addition, there are treatments that are based on the implementation of electrodes in the brain of patients with Parkinson's to control the electric activity of neurons. In the same lines, optical fibers could make light getting to almost any part of the body (spatial resolution), and these organs would be radiated with light controlled by an electronic device that would regulate the intensity and length of radiation (time resolution).

Maintaining the commitment of patients to the set therapeutic guideline on the long run is a big challenge for chronic diseases. "With a slow release system from the photoactive drug, such as a coupled patch with a radiation system remotely controlled by a phone App, the doctor could control in a precise manner the release of the most efficient dose of the active drug in the place of action," says Ciruela.

Although the clinical application of this photoactive in patients is still far, this pharmacological innovation could lead the way to a research on new therapeutical solutions for this chronic disease. The new article, published in Journal of Controlled Release, is therefore a step forward in the field of pharmacology to design new therapeutical strategies with photo-sensitive molecules and to set innovative clinical protocols to improve patients' quality of life.

Explore further: First photoactive drug for pain treatment

More information: Jaume Taura et al. Remote control of movement disorders using a photoactive adenosine A 2A receptor antagonist, Journal of Controlled Release (2018). DOI: 10.1016/j.jconrel.2018.05.033

Related Stories

First photoactive drug for pain treatment

April 12, 2017
A team of the Institute of Neurosciences of the University of Barcelona has participated in the design of the first light-activated drug, JF-NP-26, for the treatment of pain, according to a study with animal models published ...

Investigators eye new target for treating movement disorders

January 19, 2018
Blocking a nerve-cell receptor in part of the brain that coordinates movement could improve the treatment of Parkinson's disease, dyskinesia and other movement disorders, researchers at Vanderbilt University have reported.

Tactic for controlling motor symptoms of advanced Parkinson's disease

January 25, 2018
Standard drug treatment for Parkinson's disease can over time induce motor complications that reduce the effectiveness of restoring mobility. These complications include abnormal involuntary movements known as dyskinesias. ...

New drug may treat and limit progression of Parkinson's disease

July 31, 2017
Researchers at Binghamton University have developed a new drug that may limit the progression of Parkinson's disease while providing better symptom relief to potentially hundreds of thousands of people with the disease.

Body movements just need a 'puff' of dopamine to get started

January 31, 2018
From morning til night, we never stop executing movements at the right time and speed. But patients suffering from Parkinson's disease lose this natural control over their voluntary movements.

Recommended for you

New evidence sheds light on how Parkinson's disease may happen

June 14, 2018
Researchers at Baylor College of Medicine and Texas Children's Hospital have identified unexpected new key players in the development of an early onset form of Parkinson's disease called Parkinsonism. These key players are ...

Scientists unravel molecular mechanisms of Parkinson's disease

June 12, 2018
Detailed brain cell analysis has helped researchers uncover new mechanisms thought to underlie Parkinson's disease.

First photoactive drug to fight Parkinson's disease

June 8, 2018
An international team has designed the first potentially therapeutic photoactive drug, MRS7145, to fight Parkinson's disease, according to the new article in Journal of Controlled Release.

Researchers address sleep problems in Parkinson's disease

June 7, 2018
A team of researchers at VIB and KU Leuven has uncovered why people with a hereditary form of Parkinson's disease suffer from sleep disturbances. The molecular mechanisms uncovered in fruit flies and human stem cells also ...

Drugs that suppress immune system may protect against Parkinson's

May 31, 2018
People who take drugs that suppress the immune system are less likely to develop Parkinson's disease, according to a study from Washington University School of Medicine in St. Louis.

Early synaptic dysfunction found in Parkinson's Disease

May 24, 2018
Northwestern Medicine scientists identified a cellular mechanism that leads to neurodegeneration in patients with Parkinson's disease, according to a study published in Proceedings of the National Academy of Sciences.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.